Edgestream Partners’s TG Therapeutics TGTX Stock Holding History

Edgestream Partners’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.8M	Sell	69,193 -99,158	-59%	-$4.06M	0.11%	340
2026 Q1	$5.59M	Buy	+168,351	New	+$5.02M	0.18%	200
2025 Q2	–	Sell	-65,249	Closed	-$2.57M	–	1063
2025 Q1	$2.57M	Buy	65,249 +11,511	+21%	+$387K	0.09%	420
2024 Q4	$1.62M	Buy	+53,738	New	+$1.54M	0.07%	441
2023 Q4	–	Sell	-90,227	Closed	-$754K	–	1060
2023 Q3	$754K	Buy	90,227 +62,998	+231%	+$878K	0.06%	484
2023 Q2	$676K	Buy	+27,229	New	+$703K	0.06%	458

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Edgestream Partners's TGTX Position: Q2 2026 in Review

Edgestream Partners reduced its TG Therapeutics (TGTX) stake by 59% in Q2 2026, selling an estimated $4.06M and leaving 69,193 shares worth $3.8M. The position accounts for 0.11% of the portfolio, ranked #340.

Edgestream Partners first reported a position in TGTX in Q2 2023 and has held it in 6 quarters since. The position peaked at $5.59M in Q1 2026. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Edgestream Partners held 69,193 shares of TG Therapeutics worth $3.8M as of Q2 2026.
Edgestream Partners sold 99,158 TG Therapeutics shares in Q2 2026, an estimated $4.06M.
TG Therapeutics made up 0.11% of Edgestream Partners's portfolio in Q2 2026, its #340 holding.
Edgestream Partners first reported a position in TG Therapeutics in Q2 2023 and has held it in 6 quarters since.
Edgestream Partners's TG Therapeutics position peaked at $5.59M in Q1 2026.
428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.